Pre-clinical evaluation of cell engager therapeutics for pemphigoid diseases
This research aims to evaluate the efficacy of novel cell engager molecules targeting autoreactive B- or T-cells in pre-clinical mouse models of pemphigoid diseases. The study leverages extensive expertise in pemphigoid disease models to validate therapeutic approaches.
Overview
This research initiative focuses on testing novel cell engager molecules designed to target autoreactive B- or T-cells in immunization-induced mouse models of pemphigoid diseases. Pemphigoid diseases are autoimmune disorders characterized by the formation of disease-causing autoantibodies. The study builds upon over 15 years of expertise in pre-clinical model systems to validate these therapeutic strategies, aiming to reduce clinical disease activity.
Technical specifications
Key features:
- Utilizes immunization-induced mouse models to mimic pemphigoid disease conditions.
- Targets CD4 T cells and B cells responsible for autoantibody formation.
- Conducts a 4-week treatment period following randomization based on disease severity.
- Employs a combination of isotype controls, antibody-based cell depletors, and reference treatments.
- Measures primary and secondary endpoints to assess clinical efficacy and gather biological materials for further analysis.
Technology readiness level
The current stage of this research is at Technology Readiness Level 3, indicating active research and development with experimental validation in pre-clinical models. Further validation is planned to move towards clinical application.
About Universität zu Lübeck
Universität zu Lübeck is a small public research university of about 6,000 students with a focused, interdisciplinary character and a strong orientation toward translation. Its campus is closely integrated with the Lübeck site of University Hospital Schleswig-Holstein, giving corporate R&D teams a pathway from research and clinical insight toward validation and care. The Hanse Innovation Campus Lübeck connects the university with neighboring higher-education and research institutions, clinical partners, and companies in a regional innovation cluster. A central technology-transfer office supports contract research, cooperation agreements, patents, licensing, and spin-offs, with research funded through the DFG, Germany’s BMBF, and European Union programs.
delivered to your inbox.